ACS Nano · 2024 · 30 citations · 31 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmunotherapy For Brain TumorsImmunotherapy For Solid TumorsAdaptive Antitumor ImmunityCancer Immunotherapy NanoparticlesEffector T Cell InfiltrationGlioblastoma Immune EvasionGlioblastoma ImmunotherapyHypoxia-driven ImmunosuppressionImmune Checkpoint Inhibitor TherapyTumor Microenvironment Hypoxia
The currently available immune checkpoint therapy shows a disappointing therapeutic efficacy for glioblastoma multiforme (GBM), and it is of great importance to discover better immune checkpoints and develop innovative targeting strategies. The discovered metabolic immune checkpoint ecto-5-nucleotidase (CD73) in a tumor contributes to its immune evasion due to the dysregulation of extracellular adenosine (ADO), which significantly inhibits the function of antitumor T cells and increases the activity of immunosuppressive cells. Herein, we drastically inhibit the expression of CD73 to reduce the production of ADO by using versatile Au@Cu 2– x Se nanoparticles (ACS NPs). ACS NPs can decrease the expression of CD73 by alleviating the tumor hypoxia through their Fenton-like reaction to weaken the ADO-driven immunosuppression for enhancing antitumor T cell infiltration and activity of GBM. The copper ions (Cu 2+ ) released from ACS NPs can chelate with disulfide, leading to the formation of cytotoxic bis( N, N -diethyldithiocarbamate)-copper complex (CuET), which can be combined with radiotherapy to recruit more antitumor T cells to infiltrate into the tumor site. Based on the inhibition of CD73 to promote the infiltration and activity of antitumor T cells, a cascade of enhancing GBM immunotherapy effects can be achieved. The significant increase in CD8 + T and CD4 + T cells within the tumor and the memory T cells in the spleen effectively reduces tumor size by 92%, which demonstrates the excellent efficacy of immunotherapy achieved by a combination of metabolic immune checkpoint CD73 inhibition with chemoradiotherapy. This work demonstrates that modulation of CD73-mediated tumor immunosuppression is an important strategy of improving the outcome of GBM immunotherapy.
31
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Lukas F. Mager, Regula Burkhard, Nicola Pett et al. · Science · 2020 · 1.3K citations
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4
Zdeněk Škrott, Martin Mistrík, Klaus Kaae Andersen et al. · Nature · 2017 · 789 citations
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
Sangeeta Goswami, Thomas Walle, Andrew Cornish et al. · Nature Medicine · 2019 · 377 citations · Full text
Medicine, Immunology, Oncology +16
Targeting CD73 in the tumor microenvironment with MEDI9447
Carl Hay, Erin Sult, Qihui Huang et al. · OncoImmunology · 2016 · 288 citations · Full text
Medicine, Immunology, Oncology +17